Gastroenterology

Leffler describes progress made in the understanding of celiac disease but points to continued challenges in diagnosis and management.

Jeemin Kwon, MD, describes the role GI symptom-related anxiety plays in shaping dietary patterns and altering the gut microbiome in patients with IBS.

A pair of experts discuss their research on trends in the use of GLP-1 RAs in patients with IBD as well as their safety and efficacy in this patient population.

Discover an approach to diagnosing food sensitivities, offering personalized diets and significant symptom relief through testing methods.

Horst explains the importance of addressing depression and anxiety in patients with IBD and steps clinicians can take to support their patients’ mental health.

EBX-102-02 was well tolerated and led to clinically meaningful improvements across multiple symptom domains in patients with IBS-C.

Subgroup analysis findings highlight duvakitug’s efficacy and tolerability across different levels of inflammation in ulcerative colitis.

Biomarker-informed molecular guidance led to greater achievement of disease control compared with standard “best care” for IBD anti-TNF therapy.

Gregory Cote, MD, reviews SHARP trial data suggesting ERCP with miES does not reduce acute pancreatitis risk in acute recurrent pancreatitis and pancreas divisum.

Anthony Kerbage, MD, explains the heightened risk of repeat screening colonoscopy among patients with a primary language other than English.

Fendrick describes patients’ desire for green screening options and reviews findings from a study comparing the environmental impact of screening tools.

Gold explains misconceptions about who is affected by EoE and describes the importance of understanding the impact of SDoH in this patient population.

Fendrick describes the importance of follow-up colonoscopy after a positive result on a noninvasive test and factors influencing follow-up rates.

Pontecorvi describes the unique features of the EndoZip system and reviews findings from a study on its use for treating obesity-related comorbidities.

Compared with non-users, the cannabis use cohort showed significantly greater risks of acute pancreatitis flare pancreatic cancer, and all-cause mortality.

Feuerstadt explains recent advances in treating recurrent C diff and reviews new data on the safety and administration of fecal microbiota, live-jslm (Rebyota).

Long-term childhood outcomes were comparable in biologic-exposed and unexposed infants born to mothers with inflammatory bowel disease.

May describes differences between colorectal cancer screening tests and which might be right for patients based on their preferences and values.

May discusses currently available NITs for colorectal cancer screening, the continued importance of colonoscopy, and the emergence of blood-based tests.

Our Q1 recap for gastroenterology spotlights regulatory updates, clinical trial data, and new research and guidance about colorectal cancer screening.

Investigators encourage further study of treatment and therapy methods for childhood IBD.

The March 2025 month in review spotlights an RX Review about USMSTF guidance on bowel prep for colonoscopy, an FDA approval, and clinical trial updates.

Our top 5 headlines featured new migraine guidelines, the benefit of automated insulin delivery for type 2 diabetes, and 3 key FDA decisions.

Examining recent developments in ASUC management, including predictive markers for colectomy, new treatment approaches, and ongoing challenges.

The approval for moderately to severely active Crohn disease marks the fourth indication for Johnson and Johnson's IL-23 inhibitor.